TY - JOUR
T1 - Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
AU - Devonshire, Virginia
AU - Havrdova, Eva
AU - Radue, Ernst Wilhelm
AU - O'Connor, Paul
AU - Zhang-Auberson, Lixin
AU - Agoropoulou, Catherine
AU - Haering, Dieter Adrian
AU - Francis, Gordon
AU - Freedoms Study Group
AU - Hupperts, Raymond
AU - Kappos, Ludwig
PY - 2012/5
Y1 - 2012/5
N2 - Background fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (ms). In the phase 3, 2-year freedoms (fty720 research evaluating effects of daily oral therapy in ms) study, fingolimod significantly reduced annualised relapse rates (arrs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics.
AB - Background fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (ms). In the phase 3, 2-year freedoms (fty720 research evaluating effects of daily oral therapy in ms) study, fingolimod significantly reduced annualised relapse rates (arrs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics.
U2 - 10.1016/S1474-4422(12)70056-X
DO - 10.1016/S1474-4422(12)70056-X
M3 - Article
SN - 1474-4422
VL - 11
SP - 420
EP - 428
JO - Lancet Neurology
JF - Lancet Neurology
IS - 5
ER -